Evidence map›Paper›PMID 32471903›Full record

ArticleAnnals of the rheumatic diseases2020

Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.

Milena Gianfrancesco, Kimme L Hyrich, Sarah Al-Adely, Loreto Carmona, Maria I Danila, Laure Gossec, Zara Izadi, Lindsay Jacobsohn, Patricia Katz, Saskia Lawson-Tovey and 19 more

Registry-linked trialOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of the rheumatic diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04754698 (Immunogenicity and Safety of the CoronaVac Vacccine in Patients With Autoimmune Rheumatic Diseases and People Living With HIV/AIDS), which is not on this map. Cited by 648 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
648citing papers in PubMed, 1 pooled it
26.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04754698 phase4completednot on this mapstarted 2021, after this paper: background citation

Immunogenicity and Safety of the CoronaVac Vacccine in Patients With Autoimmune Rheumatic Diseases and People Living With HIV/AIDS

TypeinterventionalSponsorUniversity of Sao Paulo General HospitalRan2021 to 2024Enrolled2,196ConditionsRheumatic Disease, HIV Infections, AIDS, Safety IssuesArmsCoronaVac
3 · Its place in the literature

Who cites it

648 citing papers in PubMed, 1 synthesis or guideline pooled it, 1,173 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Materials today. Bio · 2026
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Observational
  13. Article
  14. Article
  15. Article
  16. Triple Pulmonary Coinfection with SARS-CoV-2,Life (Basel, Switzerland) · 2025
    Article
  17. Article
  18. Article
  19. Article
  20. Article

588 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

29 authors at 17 institutions in 9 countries.

Milena Gianfrancesco *Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, California, USA.
Kimme L Hyrich *Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester, UK.
Sarah Al-AdelyCentre for Epidemiology Versus Arthritis, The University of Manchester, Manchester, UK.
Loreto CarmonaInstituto de Salud Musculoesquelética, Madrid, Spain.
Maria I DanilaDivision of Clinical Immunology and Rheumatology, Department of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA.
Laure GossecInstitut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, Sorbonne Universite, Paris, France.ORCID 0000-0002-4528-310X
Zara IzadiDepartment of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, California, USA.
Lindsay JacobsohnDepartment of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, California, USA.
Patricia KatzDepartment of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, California, USA.
Saskia Lawson-ToveyNational Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester, Greater Manchester, UK.
Elsa F MateusPortuguese League Against Rheumatic Diseases (LPCDR), Lisbon, Portugal.
Stephanie RushDepartment of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, California, USA.
Gabriela SchmajukDepartment of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, California, USA.
Julia SimardHealth Research & Policy, Division of Epidemiology and Department of Medicine, Division of Immunology & Rheumatology, Stanford School of Medicine, Stanford, California, USA.
Anja StrangfeldForschungsbereich Epidemiologie, Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany.
Laura TrupinDepartment of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, California, USA.
Katherine D WyshamUniversity of Washington, Seattle, Washington, USA.
Suleman BhanaCrystal Run Healthcare, Middletown, New York, USA.
Wendy CostelloIrish Children's Arthritis Network (iCAN), Tipperary, Ireland.
Rebecca GraingerDepartment of Medicine, University of Otago, Wellington, New Zealand.
Jonathan S HausmannBoston Children's Hospital, Boston, Massachusetts, USA.
Jean W LiewUniversity of Washington, Seattle, Washington, USA.
Emily SirotichDepartment of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.
Paul SufkaHealthpartners, St Paul, Minnesota, USA.
Zachary S WallaceHarvard Medical School, Boston, Massachusetts, USA.
Jinoos Yazdany *Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, California, USA.
Pedro M Machado *Centre for Rheumatology & Department of Neuromuscular Diseases, University College London (UCL), London, UK.ORCID 0000-0002-8411-7972
Philip C Robinson *Faculty of Medicine, The University of Queensland, Herston, Queensland, Australia philip.robinson@uq.edu.au.ORCID 0000-0002-3156-3418
COVID-19 Global Rheumatology Alliance
University of California, San Francisco · USUniversity of Manchester · GBUniversity of Washington · USBoston Children's Hospital · USCanadian Arthritis Patient Alliance · CACrystal Run Healthcare · USGerman Rheumatism Research Centre · DEHarvard University · USHealthPartners · USInserm · FRInstituto de Salud Musculoesquelética · ESLondon North West Healthcare NHS Trust · GBPortuguese League Against Epilepsy · PTStanford Medicine · USThe University of Queensland · AUUniversity of Alabama at Birmingham · USUniversity of Otago · NZ

Funding

RESOURCE-BASED CENTER FOR THE ADVANCEMENT OF PRECISION MEDICINE IN RHEUMATOLOGYP30AR070155 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Mary C Nakamura · 2016 to 2026
$8.2M
Advancing Quality and Outcomes Measurement in RheumatologyK24AR074534 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jinoos Yazdany · 2019 to 2026
$1.5M
Computational methods using electronic health records and registry data to detect and predict clinical outcomes in rheumatic diseaseK01AR075085 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GIANFRANCESCO, MILENA ANNE · 2019 to 2022
$458k
NIAMS NIH HHS K01 AR075085NIAMS NIH HHS K24 AR074534NIAMS NIH HHS P30 AR070155
6 · The paper itself

Abstract

objectivesCOVID-19 outcomes in people with rheumatic diseases remain poorly understood. The aim was to examine demographic and clinical factors associated with COVID-19 hospitalisation status in people with rheumatic disease.

methodsCase series of individuals with rheumatic disease and COVID-19 from the COVID-19 Global Rheumatology Alliance registry: 24 March 2020 to 20 April 2020. Multivariable logistic regression was used to estimate ORs and 95% CIs of hospitalisation. Age, sex, smoking status, rheumatic disease diagnosis, comorbidities and rheumatic disease medications taken immediately prior to infection were analysed.

resultsA total of 600 cases from 40 countries were included. Nearly half of the cases were hospitalised (277, 46%) and 55 (9%) died. In multivariable-adjusted models, prednisone dose ≥10 mg/day was associated with higher odds of hospitalisation (OR 2.05, 95% CI 1.06 to 3.96). Use of conventional disease-modifying antirheumatic drug (DMARD) alone or in combination with biologics/Janus Kinase inhibitors was not associated with hospitalisation (OR 1.23, 95% CI 0.70 to 2.17 and OR 0.74, 95% CI 0.37 to 1.46, respectively). Non-steroidal anti-inflammatory drug (NSAID) use was not associated with hospitalisation status (OR 0.64, 95% CI 0.39 to 1.06). Tumour necrosis factor inhibitor (anti-TNF) use was associated with a reduced odds of hospitalisation (OR 0.40, 95% CI 0.19 to 0.81), while no association with antimalarial use (OR 0.94, 95% CI 0.57 to 1.57) was observed.

conclusionsWe found that glucocorticoid exposure of ≥10 mg/day is associated with a higher odds of hospitalisation and anti-TNF with a decreased odds of hospitalisation in patients with rheumatic disease. Neither exposure to DMARDs nor NSAIDs were associated with increased odds of hospitalisation.

Indexed as

AdolescentAdultAgedAnti-Inflammatory Agents, Non-SteroidalAntimalarialsAntirheumatic AgentsArthritis, PsoriaticArthritis, RheumatoidBetacoronavirusBiological ProductsCoronavirus InfectionsCOVID-19FemaleGlucocorticoidsHospitalizationHumansAnti-Inflammatory Agents, Non-SteroidalAntimalarialsAntirheumatic AgentsBiological ProductsGlucocorticoidsJanus Kinase InhibitorsPrednisoneTumor Necrosis Factor Inhibitorsarthritis, rheumatoidhydroxychloroquinelupus erythematosus, systemicmethotrexatetumor necrosis factor inhibitors

Identifiers

PMID32471903
PMCPMC7299648
OpenAlexW3024016727

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.